Sun Juxian, Guo Rongping, Bi Xinyu, Wu Mengchao, Tang Zhaoyou, Lau Wan Yee, Zheng Shusen, Wang Xuehao, Yu Jinming, Chen Xiaoping, Fan Jia, Dong Jiahong, Chen Yongjun, Cui Yunfu, Dai Chaoliu, Fang Chihua, Feng Shuang, Ji Zhili, Jia Weidong, Jia Ningyang, Li Gong, Li Jing, Li Qiu, Li Jiangtao, Liang Tingbo, Liu Lianxin, Lu Shichun, Lv Yi, Mao Yilei, Meng Yan, Meng Zhiqiang, Shen Feng, Shi Jie, Sun Huichuan, Tao Kaishan, Teng Gaojun, Wan Xuying, Wen Tianfu, Wu Liqun, Xia Jinglin, Ying Mingang, Zhai Jian, Zhang Leida, Zhang Xuewen, Zhang Zhiwei, Zhao Haiping, Zheng Donghai, Zhi Xuting, Zhou Jie, Zhou Cuncai, Zhou Jian, Zeng Zhaochong, Zhu Kangshun, Chen Minshan, Cai Jianqiang, Cheng Shuqun
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Liver Cancer. 2022 Mar 17;11(4):315-328. doi: 10.1159/000523997. eCollection 2022 Jul.
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.
门静脉癌栓（PVTT）非常常见，且在肝细胞癌（HCC）的预后及临床分期中起主要作用。我们于2016年发布了该指南的第一版，并于2018年进行了修订。在过去几年中，出现了许多关于PVTT治疗的新证据，尤其是新型靶向药物和免疫检查点抑制剂的问世，它们进一步改善了PVTT的预后。因此，中国抗癌协会和中国医师协会对2018版指南进行了修订，以适应PVTT治疗的发展。中国未来针对伴有PVTT的HCC的治疗策略将取决于更多未来临床试验的新证据。
Zotero 插件